101 related articles for article (PubMed ID: 18694307)
1. Water-dispersed single-wall carbon nanohorns as drug carriers for local cancer chemotherapy.
Murakami T; Sawada H; Tamura G; Yudasaka M; Iijima S; Tsuchida K
Nanomedicine (Lond); 2008 Aug; 3(4):453-63. PubMed ID: 18694307
[TBL] [Abstract][Full Text] [Related]
2. Solubilization of single-wall carbon nanohorns using a PEG-doxorubicin conjugate.
Murakami T; Fan J; Yudasaka M; Iijima S; Shiba K
Mol Pharm; 2006; 3(4):407-14. PubMed ID: 16889434
[TBL] [Abstract][Full Text] [Related]
3. Single-walled carbon nanohorns as drug carriers: adsorption of prednisolone and anti-inflammatory effects on arthritis.
Nakamura M; Tahara Y; Ikehara Y; Murakami T; Tsuchida K; Iijima S; Waga I; Yudasaka M
Nanotechnology; 2011 Nov; 22(46):465102. PubMed ID: 22024636
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound enhanced antitumor activity of liposomal doxorubicin in mice.
Hagtvet E; Evjen TJ; Olsen DR; Fossheim SL; Nilssen EA
J Drug Target; 2011 Sep; 19(8):701-8. PubMed ID: 21524240
[TBL] [Abstract][Full Text] [Related]
5. Dispersion of cisplatin-loaded carbon nanohorns with a conjugate comprised of an artificial peptide aptamer and polyethylene glycol.
Matsumura S; Ajima K; Yudasaka M; Iijima S; Shiba K
Mol Pharm; 2007; 4(5):723-9. PubMed ID: 17685580
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of in vivo anticancer effects of cisplatin by incorporation inside single-wall carbon nanohorns.
Ajima K; Murakami T; Mizoguchi Y; Tsuchida K; Ichihashi T; Iijima S; Yudasaka M
ACS Nano; 2008 Oct; 2(10):2057-64. PubMed ID: 19206452
[TBL] [Abstract][Full Text] [Related]
7. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models.
Peer D; Margalit R
Neoplasia; 2004; 6(4):343-53. PubMed ID: 15256056
[TBL] [Abstract][Full Text] [Related]
8. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model.
Roa WH; Azarmi S; Al-Hallak MH; Finlay WH; Magliocco AM; Löbenberg R
J Control Release; 2011 Feb; 150(1):49-55. PubMed ID: 21059378
[TBL] [Abstract][Full Text] [Related]
9. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
10. Targeted killing of cancer cells in vivo and in vitro with IGF-IR antibody-directed carbon nanohorns based drug delivery.
Li N; Zhao Q; Shu C; Ma X; Li R; Shen H; Zhong W
Int J Pharm; 2015 Jan; 478(2):644-54. PubMed ID: 25510600
[TBL] [Abstract][Full Text] [Related]
11. Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin.
Studenovsky M; Ulbrich K; Ibrahimova M; Rihova B
Eur J Pharm Sci; 2011 Jan; 42(1-2):156-63. PubMed ID: 21075206
[TBL] [Abstract][Full Text] [Related]
12. Development of anti-HB-EGF immunoliposomes for the treatment of breast cancer.
Nishikawa K; Asai T; Shigematsu H; Shimizu K; Kato H; Asano Y; Takashima S; Mekada E; Oku N; Minamino T
J Control Release; 2012 Jun; 160(2):274-80. PubMed ID: 22020380
[TBL] [Abstract][Full Text] [Related]
13. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo.
Han HS; Lee J; Kim HR; Chae SY; Kim M; Saravanakumar G; Yoon HY; You DG; Ko H; Kim K; Kwon IC; Park JC; Park JH
J Control Release; 2013 Jun; 168(2):105-14. PubMed ID: 23474029
[TBL] [Abstract][Full Text] [Related]
14. Nanodiamonds-mediated doxorubicin nuclear delivery to inhibit lung metastasis of breast cancer.
Xiao J; Duan X; Yin Q; Zhang Z; Yu H; Li Y
Biomaterials; 2013 Dec; 34(37):9648-56. PubMed ID: 24016858
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
[TBL] [Abstract][Full Text] [Related]
16. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
17. Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab')(2) for hepatocellular carcinoma.
Jin C; Qian N; Zhao W; Yang W; Bai L; Wu H; Wang M; Song W; Dou K
Biomacromolecules; 2010 Sep; 11(9):2422-31. PubMed ID: 20831277
[TBL] [Abstract][Full Text] [Related]
18. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
[TBL] [Abstract][Full Text] [Related]
19. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
[TBL] [Abstract][Full Text] [Related]
20. Nanoscaled poly(L-glutamic acid)/doxorubicin-amphiphile complex as pH-responsive drug delivery system for effective treatment of nonsmall cell lung cancer.
Li M; Song W; Tang Z; Lv S; Lin L; Sun H; Li Q; Yang Y; Hong H; Chen X
ACS Appl Mater Interfaces; 2013 Mar; 5(5):1781-92. PubMed ID: 23410916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
